Group 1 - The company MIRXES-B (02629) plans to conduct an initial public offering (IPO) from May 15 to May 20, 2025, with a total of 46.62 million shares being offered globally, where 10% is allocated for Hong Kong and 90% for international markets [1] - The offering price is set at HKD 23.30 per share, with trading expected to commence on May 23, 2025, at 9:00 AM on the Hong Kong Stock Exchange [1] - Founded in 2014 and headquartered in Singapore, the company specializes in microRNA (miRNA) technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets, including Singapore and China [1] Group 2 - The estimated net proceeds from the global offering, calculated at the offering price of HKD 23.30 per share, will be approximately HKD 880.5 million [2] - The intended use of the net proceeds includes 51% for research and development, regulatory filings, production, and commercialization of the core product GASTROClearTM; 24% for ongoing and planned R&D for pipeline products; 15% to enhance and integrate the company's end-to-end capabilities; and 10% for working capital and general corporate purposes [2] - The company has entered into cornerstone investment agreements with Beijing Xunrui Enterprise Management Partnership (Limited Partnership) and Evergreen Gate Limited, with cornerstone investors agreeing to subscribe for USD 57.92 million under certain conditions [2]
MIRXES-B5月15日-5月20日招股 拟全球发售4662万股
Zhi Tong Cai Jing·2025-05-14 22:56